

## Hyperuricemia and Risk of Atrial Fibrillation

Yuansheng Liu

*Peking University People's Hospital.*

### Abstract

The association between SUA levels and AF is currently poorly known. We reviewed the literature on the association between AF and hyperuricemia. The association between SUA level and AF has been demonstrated. SUA levels are associated with an increased risk for future AF in both sexes. And elevated SUA levels strongly correlate with an increased incidence of AF in patients with type 2 diabetes mellitus. Moreover, hyperuricemia was in connection with endothelial dysfunction, oxidative stress, systemic inflammatory markers, insulin resistance and LA size.

### Introduction

Atrial fibrillation (AF) is a clinically common arrhythmia and preferentially afflicts elderly persons.<sup>1</sup> The main risk factors for AF are complicated and multifactorial. A number of clinical risk factors for the development of AF have been confirmed, including old age, male gender, rheumatic heart disease, hypertension, congestive heart failure, hyperthyroidism, chronic kidney disease and diabetes mellitus. Although the pathophysiology of AF remains incompletely understood, accumulative evidences indicated that oxidative stress and inflammation were involved in the process of atrial remodeling which predisposed patients to AF.<sup>2,3</sup> In addition, the consistent relationship between elevated serum uric acid levels and circulating inflammatory markers has been reported. Serum uric acid (SUA) is the breakdown product of purine catabolism. Increased levels are associated with hypertension, kidney disease, obesity, hyperlipidaemia, diabetes, and cardiovascular disease. The association between SUA levels and AF is currently poorly known. In our previous study, the results also showed that low serum albumin and hyperuricemia were independently correlated with the presence of AF compared with the non-AF group.<sup>4</sup> Previous studies also supported the hypothesis that hyperuricemia causes vascular disease via endothelial dysfunction.

### Key Words:

Hyperuricemia, Atrial Fibrillation, Oxidative Stress, Inflammatory.

### Disclosures:

None.

### Corresponding Author:

Yuansheng Liu, Ph.D. Emergency Department,  
Peking University People's Hospital,  
Xizhimen South Street,  
Beijing 100044,  
China.

It is clear that further studies are needed to determine whether the SUA level increases the risk of AF directly or indirectly.<sup>4,5</sup>

### Xanthine Oxidase and Serum Uric Acid

SUA derives from the conversion of hypoxanthine to xanthine and of xanthine to SUA, which reactions are catalyzed by xanthine oxidase. Ischemia and cellular damage can promote xanthine accumulation creating a substrate for xanthine oxidase. This enzyme uses molecular oxygen as electron acceptor and leads to the formation of free radical superoxide anion, then promoting oxidative stress. The highest activity of xanthine oxidase is detected in endothelium, intestine, and liver. Among them, endothelial xanthine oxidase plays a crucial role in the cardiovascular oxidative stress. SUA has emerged as a simple and independent marker of morbidity and mortality in a variety of cardiovascular disease states including coronary artery disease, heart failure and AF. In the pathophysiological conditions, SUA reflects upregulated xanthine oxidase activity. Furthermore, SUA may represent an endogenous signal of cell injury activating the cellular immune response. In fact, SUA has been associated with a pro-inflammatory state in human subjects.<sup>6</sup> Masao Sakabe et al. provided experimental evidence that a xanthine oxidase inhibitor, allopurinol, prevents AF associated with congestive heart failure. This results suggest that xanthine oxidase may play an important role in the formation of AF substrates and enhancement of atrial vulnerability, and might be a novel target of AF therapy. The effect of allopurinol to prevent both electrical and structural remodeling, which has different manifestations, is noteworthy.<sup>7</sup>

### Hyperuricemia and Atrial Fibrillation

A possible direct link between SUA and AF has barely been addressed.<sup>8</sup> Several studies have reported an association between SUA and AF, which were summarized in Table 1.<sup>7-12</sup> An increasing body of evidence suggests that SUA may represent a marker of AF risk.

**Table 1:** Summary of the studies investigating the relationship between SUA and AF

Author (year)	Study design	Patient number	Age, years	Main findings
Letsas et al. [9]	Cross-section	Paroxysmal AF: 45 Persistent AF: 41 Non-AF: 86	Paroxysmal AF: 67.4 ± 8.8 Persistent AF: 71.9 ± 9.9 Non-AF: 61.3 ± 14.7	SUA level was associated with permanent AF (OR = 2.712; 95% CI = 1.327–3.555; p = 0.002).
Liu et al. [10]	Cross-section	451 patients with hypertension – AF: 50 Non-AF: 401	AF: 61.8 ± 9.2 Non-AF: 54.9 ± 12.1	Independent association between SUA level and AF was noted (OR = 1.008; 95% CI = 1.003–1.013; p = 0.002).
Tamariz et al. [11]	Longitudinal cohort	15,382 AF-free patients (1085 cases of new-onset AF during the median follow-up duration of 16.8 years)	45–64 years at enrollment	Baseline SUA level was a predictor of AF (HR = 1.16; 95%CI = 1.06–1.26 per 1 standard deviation of increasing SUA level; p < 0.01). Subgroup analyses showed that baseline SUA levels were associated with AF in blacks and women, but not in whites and men.
Suzuki et al. [12]	Cross-section	AF: 1131 Non-AF: 6024	Male: 57.1 ± 13.8 Female: 60.7 ± 15.2	SUA level was associated with permanent AF Adjusted OR for AF was 1.176 (95% CI = 0.935–1.478) in males and 1.888 (95% CI = 1.278–2.790) in females
Tze-Fan Chao et al. [13]	Longitudinal cohort	AF:2339 (1.9%) Non-AF: 120,185	48.8 ± 10.9 years at enrollment	SUA level was associated with permanent AF Adjusted hazard ratio (95% CI) 1.191 (1.098–1.292); p < 0.001
K. Letsas et al [14]	cross-section	Control (n=48) Paroxysmal AF (n=45) Permanent AF (n=41)	Paroxysmal AF: 67.4 ± 8.8 Permanent AF: 71.9 ± 9.9 Control: 61.3 ± 14.7	SUA level was associated with permanent AF Control:5.1 ± 1.3 Paroxysmal AF:5.7 ± 1.1 Permanent AF: 6.7 ± 1.4 p < 0.001

The association between SUA level and AF has been demonstrated. Moreover, Nyrnes A et al. found that serum uric acid levels in men are higher than in women throughout life, although SUA levels increase after menopause, and that baseline SUA was associated with an increased risk for future AF in both sexes. In addition, the occurrence of AF increases with age, and the fact that SUA levels in women, in contrast to men, increase with age may account for the higher risk estimates seen in women.<sup>8</sup> Furthermore, in a small observational study, Letsas et al. showed a stepwise increase of SUA levels in patients with paroxysmal AF and permanent AF compared to control subjects, while after multivariate analysis, SUA was an independent predictor of permanent AF.<sup>9</sup> Also, in a retrospective observational study of hospitalized patients over 40 years an independent association between high SUA levels and AF (paroxysmal or persistent) was evident.<sup>10</sup> In the ARIC study, a large prospective cohort study, elevated SUA was associated with a greater risk of AF development during the follow-up.<sup>11</sup> In the same line, a Japanese hospital-based cohort study demonstrated an independent association between SUA and AF.<sup>12</sup> Another very recent study showed that SUA levels  $\geq 8$  mg/dl was an independent predictor of AF while SUA increased significantly between the last year and the year of the first AF detection suggesting a possible involvement in AF development.<sup>6</sup> Besides, Tze-Fan Chao et al. showed that hyperuricemia was associated with a larger left atrial size and may be a novel risk factor for the development of AF.<sup>13</sup> K. Letsas et al. also found an independent association between increased levels of SUA and permanent AF.<sup>14</sup>

To date, there is few information on the relation between elevated SUA and incident AF in patients with type 2 diabetes mellitus. In a recent, Filippo Valbusa et al. reported that in a group of patients with type 2 diabetes mellitus, AF and hyperuricemia are highly prevalent. Their study demonstrated that elevated SUA levels are strongly associated with an increased incidence of AF in patients with type 2 diabetes mellitus even after adjustment for multiple clinical risk factors for AF. Notably, this association was independent of multiple clinical risk factors for AF.<sup>15</sup>

### Serum Uric Acid, Systemic Inflammation and Insulin Resistance

SUA, the final product of purine metabolism catalyzed by

xanthine oxidase, has been reported to be correlated with the levels of some inflammatory markers, such as c-reactive protein(CRP), interleukin (IL)-1, IL-6, IL-8 and tumor necrosis factor- $\alpha$ .<sup>16</sup> The underlying mechanisms of elevated SUA related to risk of AF are still poorly understood. Hyperuricemia was reported to be associated with endothelial dysfunction, oxidative stress, abnormal high levels of systemic inflammatory markers, and insulin resistance.<sup>16–19</sup> Experimental data have shown that when SUA enters cells via specific transporters (including the fructose transporter), it can act as a pro-oxidant, activating the mitogen-activated protein kinase pathway and nuclear factor k-B and inducing the release of a variety of proinflammatory mediators (e.g., IL-6, IL-8, tumor necrosis factor, and monocyte chemoattractant protein-1) and growth factors.<sup>20–24</sup>

Hyperuricemia frequently occurs in obese subjects with insulin resistance, because insulin stimulates sodium and urate reabsorption in the proximal tubule.<sup>24</sup> Moreover, SUA is frequently increased in hypertension, presumably because of the decrease in renal blood flow stimulating urate reabsorption.<sup>25</sup> Recent studies have indicated that SUA has a direct effect on smooth muscle cell proliferation,<sup>26</sup> endothelial dysfunction and decreasing nitric oxide production as well as local activation of the renin-angiotensin system.<sup>27–29</sup> The greater SUA levels could potentially lead to endothelial dysfunction and the activation of the renin-angiotensin system, which could potentially end in AF.<sup>23</sup>

Xanthine oxidoreductase is a major source of reactive oxygen species production, which has been found to be elevated in both animal and human left atria with AF.<sup>3</sup> In a recent experimental study, the enzymatic activity of xanthine oxidase in left atrial appendages was 4.4 times greater in the AF group compared to the control group.<sup>25</sup> Consequently, animal studies have shown that oxidative stress leads to the development of atrial electrical remodeling,<sup>3,30</sup> which in turn results in reentry and a decrease in nitric oxide production leading to S-nitrosylation of ion channels that can shorten the plateau phase of the action potential causing accelerated repolarization and AF.<sup>31,32</sup>

SUA promotes inflammation through the activation of pro-inflammatory cytokines (eg, IL-1 $\beta$ , IL-6, IL-8, tumor necrosis factor, and monocyte chemoattractant protein 1). On the other hand, it has been shown that SUA may exert antioxidant or pro-oxidant effects and stimulate the innate immune response through CD8+

cells. The level of SUA increases with age in both men and women. Women have lower levels of SUA than men, probably because of the uricosuric effect of estrogen.<sup>33</sup>

In animal experiments, hyperuricaemia activates the renin-angiotensin system and reduces nitric oxide. Both superoxide and nitric oxide may modulate cardiac mechanosensitive ion channels.<sup>34</sup> SUA impaired the ion channel expression through uric acid transporter1(URAT1). SUA at 9mg/dl significantly increased the mRNA level and protein level of Nav1.5, Kv1.5 and HERG channels in HL-1 mouse atrial cells. URAT1 inhibitors restored the SUA inducing the increases of both protein and mRNA level of these ion channels, indicating the involvement of URAT1 to facilitate uric acid-induced electrical remodeling, which may cause AF.<sup>35</sup>

### Serum Uric Acid and Left Atrium Dimension

Electrical and structural remodeling of left atrium (LA) is an important process involved in the pathogenesis of AF.<sup>36</sup> An enlarged LA size due to structural modeling is a well-known factor that facilitates the initiation and maintenance of AF. Besides, advanced remodeling of LA (enlarged LA size and worsening substrate) was observed in patients with insulin resistance, such as impaired fasting glucose or diabetes.<sup>37</sup> Furthermore, Tze-Fan Chao et al. found that hs-CRP and insulin resistance were higher and LA diameter was larger in patients with a higher SUA level. It indicated that increased inflammation and insulin resistance may be possible explanations for the relationship between the high SUA level and LA size.<sup>13</sup>

In a porcine atrial tachypacing model of AF, LA xanthine oxidase activity was 4.4 times greater in the paced than in the control group. Superoxide production was reduced by 85% after administration of oxypurinol (a xanthine oxidase inhibitor). Of note, in a similar porcine model, it was demonstrated that after 1 week of rapid atrial pacing the detectable xanthine oxidase was decreased in the left but not in the right atrium, suggesting that the oxidative stress was enhanced only in the left atrium. It can therefore be speculated that LA may be preferentially more sensitive to oxidative stress perhaps due to lower metabolic reserve or increased wall stress. In patients with right or left heart failure it has been demonstrated that hyperuricemia is related to elevated right or left atrial filling pressures. Also, SUA levels have been correlated with more impaired right ventricular systolic function and decreased LA work in patients with heart failure. It would therefore be speculated that SUA metabolism is implicated in atrial remodeling, indicating that increased atrial filling pressures cause structural and electrophysiological abnormalities that facilitate the development and perpetuation of AF.<sup>6</sup> Moreover, chronic heart failure is associated with hyperuricemia, increased circulating markers of inflammation, and oxidative stress. This mechanism is also present in pathogenesis of AF.<sup>38</sup>

### Conclusions:

SUA has emerged as an independent marker of AF risk. The association between SUA level and AF has been demonstrated. Baseline SUA was associated with an increased risk for future AF in both sexes. Moreover, elevated SUA levels strongly correlate with an increased incidence of AF in patients with type 2 diabetes mellitus.

Hyperuricemia was in connection with endothelial dysfunction, oxidative stress, abnormal high levels of systemic inflammatory markers, and insulin resistance. And increased inflammation and insulin resistance may be possible explanations for the relationship between the high SUA level and LA size.

### References:

1. Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. *Am J Geriatr Cardiol.* 2005; 14:56-61
2. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? *Eur Heart J.* 2006;27:136-149.
3. Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. *Int J Cardiol.* 2007;115:135-143.
4. Yuansheng Liu, Hao Liu, Lei Dong, et al. Prevalence of atrial fibrillation in hospitalized patients over 40 years old: ten-year data from the People's Hospital of Peking University. *Acta Cardiol.* 2010;65(2):221-224
5. Iacoviello M, Forleo C, Guida P, et al.: Ventricular repolarization dynamicity provides independent prognostic information toward major arrhythmic events in patients with idiopathic dilated cardiomyopathy. *J Am Coll Cardiol.* 2007; 50:225-231
6. Panagiotis Korantzopoulos, Konstantinos P. Letsas, Tong Liu. Xanthine Oxidase and Uric Acid in Atrial Fibrillation. *Front Physiol.* 2012; 3: 150
7. Sakabe M, Fujiki A, Sakamoto T, et al. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. *J Cardiovasc Electrophysiol.* 2012;23(10):1130-1135
8. Nyrnes A, Toft I, Njølstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Løchen ML. Nyrnes A, Toft I, Njølstad I, et al. Uric acid is associated with future atrial fibrillation: an 11-year follow-up of 6308 men and women--the Tromso Study. *Europace.* 2013 Aug 30. [Epub ahead of print]
9. Letsas KP, Korantzopoulos P, Filippatos GS, et al. Uric acid elevation in atrial fibrillation. *Hellenic J Cardiol.* 2010;51:209-13.
10. Liu T, Zhang X, Korantzopoulos P, Wang S, Li G. Uric acid levels and atrial fibrillation in hypertensive patients. *Intern Med.* 2011;50:799-803.
11. Tamariz L, Agarwal S, Soliman EZ, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol.* 2011;108:1272-1276.
12. Suzuki S, Sagara K, Otsuka T, et al. Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. *Circ J.* 2012;76:607-611.
13. Tze-Fan Chao, Chung-Lieh Hung, Su-Jung Chen, et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. *International Journal of Cardiology.* 2013;168(4):4027-4032
14. Konstantinos P. Letsas, Panagiotis Korantzopoulos, Gerasimos S. Filippatos, et al. Uric Acid Elevation in Atrial Fibrillation. *Hellenic J Cardiol.* 2010; 51: 209-213
15. Valbusa F, Bertolini L, Bonapace S, et al. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. *Am J Cardiol.* 2013;112(4):499-504
16. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. *Eur Heart J.* 2006;27:1174-1181.
17. Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol.* 2012;176:108-116.
18. Papezikova I, Pekarova M, Kolarova H, et al. Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production. *Free Radic Res.* 2013;47:82-88.
19. Korantzopoulos P, Letsas KP, Liu T. Xanthine oxidase and uric acid in atrial fibrillation. *Front Physiol.* 2012;3:150.
20. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med.* 2008;359:1811-1821.
21. Lippi G, Montagnana M, Franchini M, et al. The paradoxical relationship between serum uric acid and cardiovascular disease. *Clin Chim Acta.* 2008;392:1-7.
22. Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. *Am J Nephrol.* 2005;25:425-433.

23. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension*. 2003;41:1287-1293.
24. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. *Diabetes*. 2011;60:1258-1269.
25. Shinya Suzuki, Koichi Sagara, Takayuki Otsuka, et al. Gender-Specific Relationship Between Serum Uric Acid Level and Atrial Fibrillation Prevalence. *Circ J*. 2012; 76: 607 – 611
26. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. *J Biol Chem*. 1991; 266: 8604 – 8608.
27. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. *J Am Soc Nephrol*. 2005; 16: 3553 – 3562.
28. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. *Circulation*. 2002; 106: 221 – 226.
29. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. *Kidney Int*. 2004; 66: 1465 – 1470.
30. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ Res*. 2001;89:E32–E38.
31. Gonzalez DR, Treuer A, Sun QA, et al. S-nitrosylation of cardiac ion channels. *J Cardiovasc Pharmacol*. 2009;54:188 – 195.
32. Gill JS, McKenna WJ, Camm AJ. Free radicals irreversibly decrease Ca<sup>2+</sup> currents in isolated guinea-pig ventricular myocytes. *Eur J Pharmacol*. 1995;292:337–340.
33. Eiichi Watanabe. Uric Acid and Atrial Fibrillation— Cause or Other Association? *Circulation Journal* . 2012; 76:584-585
34. Dyachenko V, Rueckschloss U, Isenberg G. Modulation of cardiac mechanosensitive ion channels involves superoxide, nitric oxide and peroxynitrite. *Cell Calcium*. 2009;45:55–64.
35. Masanari Kuwabara, Koichiro Niwa, Hiroyuki Niinuma, et al. Hyperuricemia is an independent risk factor of atrial fibrillation due to electrical remodeling through activation of uric acid transporter. *JACC*. 2012; 59(13): E663
36. Lin YJ, Tsao HM, Chang SL, et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. *Am J Cardiol*. 2010;105:495–501.
37. Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. *Am J Cardiol*. 2010;106:1615–1620.
38. Gulacan Tekin, Yusuf Kenan Tekin, Ali Riza Erbay, et al. Serum Uric Acid Levels are Associated With Atrial Fibrillation in Patients With Ischemic Heart Failure. *Angiology*. 2013;64(4) 300-303